#Lipid Nanoparticles Market

[healthcaremarketanalysis]

Lipid Nanoparticles Market to Reach USD 350.5M by 2029

The Global Lipid Nanoparticles Market is expected to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, with a CAGR of 5.2%, while the LNP services market is projected to rise from USD 135.5 million in 2024 to USD 238.1 million by 2029 at a CAGR of 11.9%. Growth is driven by advancements in LNP-based pharmaceuticals, particularly in anti-cancer and mRNA therapies, though regulatory challenges and formulation issues pose potential constraints. Key opportunities include the demand for advanced drug delivery systems and scalable mRNA vaccines. The market's key players include Avanti Polar Lipids, Merck KGaA, and FUJIFILM Pharmaceuticals, with North America being the leading regional market. The sector is influenced by diverse product segments such as ionizable and PEGylated lipids, with applications spanning COVID-19 and cancer treatments.

Download PDF Brochure

Browse in-depth TOC on "Lipid Nanoparticles Market"

398 - Tables

53 - Figures

316 - Pages

Factors Influencing Market Trends

The expansion of the lipid nanoparticles market is driven by increasing research and development efforts to create lipid nanoparticle-based drugs. However, stringent regulatory requirements may impede growth.

Product Segment Insights

The market is segmented by product into ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials, with ionizable lipids leading due to their crucial role in mRNA vaccines like Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273.

LNP Type Breakdown

Segmented into solid lipid nanoparticles, nanostructured lipid carriers, and other types, the solid lipid nanoparticles segment holds the largest share, favored for vaccine production and as an alternative drug delivery carrier.

Molecule Type Distribution

The market is divided by molecule type into siRNA, mRNA, and other molecules. The mRNA segment dominates due to its effectiveness in vaccine production and the enhanced delivery capabilities of lipid nanoparticles.

Application Areas

Segmented into commercial and clinical applications, the commercial segment currently holds the largest market share due to its extensive use in vaccine production. The clinical applications segment, however, is expected to grow the fastest, driven by advancements in targeted drug delivery and personalized medicine.

End-User Analysis for Raw Materials

For raw materials, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and CDMOs, with pharmaceutical & biotechnology companies holding the largest share due to their high use of lipid nanoparticles in drug development.

Service Type Analysis

The lipid nanoparticles services market, categorized into formulation development services, manufacturing services, and other services, sees the largest share in manufacturing services. This is driven by the high demand for raw materials and ongoing requirements from pharmaceutical and biotechnology companies.

End-User Analysis for Services

The services market is segmented by end users into pharmaceutical & biotechnology companies and academic & research institutes, with pharmaceutical & biotechnology companies leading due to their need for specialized manufacturing services and expertise.

Regional Market Overview

The lipid nanoparticles market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the largest share in 2023, benefiting from advanced healthcare infrastructure and significant R&D investments. However, the Asia Pacific region is anticipated to be the fastest-growing market during the forecast period, driven by increased healthcare expenditure, government initiatives, and favorable regulatory conditions.

Request Sample Pages

Growth Drivers and Challenges

The growth of the lipid nanoparticles market is driven by their increasing use in anti-cancer and RNA-based therapies. However, stringent regulatory requirements related to lipid nanoparticles may pose challenges to market expansion.

Market Consolidation

The lipid nanoparticles market is largely consolidated, with major players such as Avanti Polar Lipids (Croda International plc), Merck KGaA, NOF CORPORATION, and Nippon Fine Chemical holding 70-75% of the global market share.

Company Profiles

Avanti Polar Lipids (US): Established in 1967, Avanti specializes in high-purity lipids for biochemical and pharmaceutical research. The company offers a broad portfolio of lipid nanoparticles and custom synthesis services, heavily investing in R&D and collaborating with academic institutions to advance lipid formulations.

Merck KGaA (Germany): This healthcare and life sciences company provides a range of lipid nanoparticles products for research and clinical applications. Merck KGaA has strengthened its RNA production capabilities and recently acquired Exelead for approximately USD 780 million to enhance its CDMO services.

NOF CORPORATION (Japan): NOF CORPORATION is a prominent chemical manufacturer known for its lipid nanoparticle formulations. In April 2024, NOF collaborated with Phosphorex to provide lipid nanoparticles using their COATSOME® SA Series, which offers efficient nucleic acid delivery with minimal toxicity. NOF continues to innovate with high-purity lipid derivatives and liposome formulations for various drug applications.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA : 1-888-600-6441

UK +44-800-368-9399

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

[globalgrowthinsights]

Liposomal and Lipid Nanoparticle Drug Delivery Systems Market: Estimation, Potential, Development, Share, and Growth

""Liposomal and Lipid Nanoparticle Drug Delivery Systems Market""provides in-depth analysis on the market status of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market, including best facts and figures, overview, definition, SWOT analysis, expert opinions, and the most recent developments worldwide. The report also computes market size, Price, Revenue, Cost Structure, Gross Margin, Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Sales, and Market Share, Forecast and Growth Rate. The report helps to determine the revenue generated by the sale of this report and technologies across various application segments.

It is projected that between 2024 and 2032, The Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market would grow at a significant rate. In 2023, the market is likely to grow rapidly and over the estimated horizon due to the growing adoption of strategies by major players. This research provides a detailed analysis of the market size, characteristics, and growth of the Liposomal and Lipid Nanoparticle Drug Delivery Systems Market industry from 2024 to 2032. It is segmented based on the product type, downstream application, and consumption area of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market. Along with introducing industry participants from a value chain viewpoint, the research also examines the top businesses.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market in these regions till the forecast period

North America

Middle East and Africa

Asia-Pacific

South America

Europe

For more Click Here : https://www.globalgrowthinsights.com

Key Attentions of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Report:

The report offers a comprehensive and broad perspective on the global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market.

The market statistics represented in different Liposomal and Lipid Nanoparticle Drug Delivery Systems Market segments offers complete industry picture.

Market growth drivers, challenges affecting the development of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market are analyzed in detail.

The report will help in the analysis of major competitive market scenario, market dynamics of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market.

Major stakeholders, key companies Liposomal and Lipid Nanoparticle Drug Delivery Systems Market, investment feasibility and new market entrants study is offered.

Development scope of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market in each market segment is covered in this report. The macro and micro-economic factors affecting the Liposomal and Lipid Nanoparticle Drug Delivery Systems Market

Advancement is elaborated in this report. The upstream and downstream components of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market and a comprehensive value chain are explained.

Browse More Details On This Report at:-  https://www.globalgrowthinsights.com/market-reports/liposomal-and-lipid-nanoparticle-drug-delivery-systems-market-101460

Global Growth Insights

Phone:

  US: +1 (888) 690-5999    UK: +44 8083 023308

Email: sales@globalgrowthinsights.com

[shubhampawrainfinium]

Beauty Revolutionized: Harnessing Nanotechnology for Next-Gen Cosmetics

The global nanotechnology in cosmetics market is poised for significant growth over the forecast period from 2022 to 2028, driven by the rising demand for advanced, effective, and innovative cosmetic products. The incorporation of nanotechnology in cosmetic formulations is gaining immense popularity, as it represents one of the most cutting-edge and rapidly advancing technologies in the sector. This approach has opened new avenues in product development, enhancing efficacy and user experience across skincare, haircare, makeup, and anti-aging products.

What is Nanotechnology in Cosmetics?

Nanotechnology in cosmetics involves using nanoparticles to improve the delivery, stability, and effectiveness of active ingredients. By reducing ingredient particles to nano-sized units, the technology allows for deeper skin penetration, increased stability, and longer-lasting effects. Types of nanotechnology applications in cosmetics include:

Nanocapsules: These are small vesicles that encapsulate active ingredients, improving targeted delivery to the skin.

Liposomes: Microscopic bubbles that carry moisturizing and active agents deep into the skin.

Nanoemulsions: Fine, stable emulsions that enhance texture and sensory properties in cosmetics.

Solid Lipid Nanoparticles (SLNs): These provide controlled release and protect active ingredients from degradation.

Get Sample pages of Report: https://www.infiniumglobalresearch.com/reports/sample-request/41182

Market Dynamics and Growth Drivers

Several factors are propelling the growth of nanotechnology in the cosmetics market:

Growing Demand for Anti-Aging and Skin Care Products: With an aging global population and a rising focus on skincare, there is a high demand for products that offer visible and lasting effects. Nanotechnology enhances the performance of active ingredients, making anti-aging creams, sunscreens, and moisturizers more effective.

Increased Awareness of Advanced Beauty Solutions: Consumers are becoming more knowledgeable about skincare science, showing a preference for products that offer innovative solutions. The appeal of nano-based products lies in their effectiveness, safety, and ability to provide enhanced benefits compared to traditional formulations.

Technological Advancements and R&D Investments: Continuous research and development efforts have led to the introduction of innovative nano-ingredients. As cosmetic companies invest in nanotechnology to develop unique formulations, the market benefits from increased product variety and advancements in cosmetic science.

Rising Consumer Awareness and Demand for Premium Products: With growing consumer awareness about skin health and the efficacy of nano-based solutions, there is a heightened demand for premium products that deliver superior performance. This trend is driving the demand for nano-based products in the luxury cosmetics segment.

Regional Analysis

North America: North America is a major market for nanotechnology in cosmetics, with a high demand for advanced beauty products. The region's robust R&D landscape and early adoption of innovative technologies support market growth.

Europe: Europe is a prominent market due to the presence of key cosmetics brands and the increasing emphasis on product efficacy and safety. European consumers have a strong preference for high-quality skincare products, which drives the demand for nano-enhanced cosmetics.

Asia-Pacific: The Asia-Pacific region is expected to exhibit the highest growth rate, supported by rising disposable incomes, a growing beauty-conscious population, and increased awareness of advanced cosmetic formulations. Markets like South Korea, Japan, and China are key contributors to this growth.

Latin America and Middle East & Africa: These regions are gradually adopting nanotechnology in cosmetics, driven by increased urbanization and awareness of skincare advancements. Growth in these areas is anticipated as consumers seek products with higher efficacy.

Competitive Landscape

The nanotechnology in cosmetics market is characterized by both established and emerging players who are focusing on product innovation and expansion to meet consumer demands. Some key companies include:

L’Oréal: A pioneer in nanotechnology in cosmetics, L'Oréal invests heavily in R&D and has introduced several nano-based skincare and haircare products. The company's commitment to innovation strengthens its market position.

Procter & Gamble: Known for its broad cosmetics portfolio, Procter & Gamble incorporates nanotechnology in select premium products, enhancing product efficacy and performance.

Unilever: With a range of popular skincare and personal care brands, Unilever leverages nanotechnology to improve the performance and user experience of its products, particularly in skincare.

Shiseido: This Japanese beauty giant is an early adopter of nanotechnology, using nano-emulsions and delivery systems in its high-end products to enhance skin benefits.

Estée Lauder: Estée Lauder’s premium skincare products utilize nanotechnology to enhance penetration and deliver targeted skincare benefits, especially in its anti-aging range.

Report Overview : https://www.infiniumglobalresearch.com/reports/global-nanotechnology-in-cosmetics-market

Challenges and Opportunities

While the outlook for nanotechnology in cosmetics is promising, the market faces challenges such as regulatory scrutiny and consumer concerns about the safety of nanoparticles. Governments and health organizations are implementing regulations to ensure the safety of nano-ingredients, which can influence the pace of new product launches.

However, opportunities abound as awareness of nanotechnology’s benefits continues to grow. The demand for premium and effective products is driving investment in new applications, including nano-formulated sunscreens, anti-aging creams, and haircare products. The growing emphasis on sustainable and clean beauty also presents opportunities for companies to develop eco-friendly nano-solutions.

Conclusion

The nanotechnology in cosmetics market is expected to grow significantly over the forecast period, driven by advancements in skincare science, consumer demand for effective products, and the benefits nanotechnology offers in enhancing product performance. As innovation and investment continue, nanotechnology is set to reshape the cosmetics landscape, creating new opportunities for growth and product development across the skincare and beauty industry.

Bottom of Form

Discover More of Our Reports

United States Process Instrumentation Market

Vietnam Fresh Food Packaging Market

[health-views-updates]

mRNA Therapeutics Market Predictions: Expert Insights on What's Next

The global mRNA Therapeutics Market Revenue, which was valued at USD 40.0 billion in 2023, is set for steady growth, projected to reach USD 46.5 billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 1.7% over the forecast period from 2024 to 2032. This growth highlights the sustained interest and investment in mRNA-based therapeutics as a pivotal tool in the future of healthcare.

The Role of mRNA Therapeutics in Modern Medicine

mRNA therapeutics represent a transformative advancement in the field of biotechnology, offering a novel approach to treating various diseases, including infectious diseases, cancer, and genetic disorders. Unlike traditional therapies, mRNA therapeutics work by instructing cells to produce specific proteins that can help treat or prevent illnesses. This mechanism has gained significant attention due to its role in the rapid development of COVID-19 vaccines, demonstrating the potential of mRNA technology to address global health challenges.

The COVID-19 pandemic underscored the importance of mRNA technology, propelling its adoption and setting the stage for further research and application. Since then, the technology has been explored for its use in other therapeutic areas, including personalized cancer vaccines, enzyme replacement therapies, and treatments for rare genetic diseases. The continued investment in research and development (R&D) is expected to drive the growth of the mRNA Therapeutics Market over the coming years.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/2671

Key Market Trends

Expansion Beyond COVID-19 Vaccines: While mRNA technology gained prominence due to its use in COVID-19 vaccines, the industry is now exploring its potential across other therapeutic areas. Companies are actively conducting clinical trials for mRNA-based treatments targeting cancer, influenza, Zika virus, and other infectious diseases.

Increased R&D Investments: The success of mRNA vaccines has led to a surge in R&D funding for mRNA-based drugs. Leading pharmaceutical companies are forming strategic partnerships to develop new mRNA therapies, with a focus on cancer immunotherapy and rare diseases. This increased funding is likely to result in the commercialization of more mRNA products in the coming years.

Advancements in Delivery Systems: One of the challenges of mRNA therapeutics has been the efficient delivery of mRNA molecules to target cells. Recent advancements in lipid nanoparticle (LNP) technology and other delivery systems have improved the stability and efficacy of mRNA drugs, making them more viable for widespread therapeutic use.

Supportive Regulatory Environment: Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have provided fast-track approvals for mRNA vaccines, reflecting a favorable regulatory environment. This support is expected to continue as new mRNA-based therapies are developed, helping expedite the market's growth.

Regional Insights

North America currently leads the mRNA Therapeutics Market, driven by the presence of leading pharmaceutical companies, advanced healthcare infrastructure, and strong government support for biotech innovation. The U.S. has been at the forefront of mRNA research, particularly through initiatives to combat COVID-19.

Europe is also a significant market for mRNA therapeutics, with countries like Germany and the UK playing key roles in R&D. The region's commitment to advancing healthcare technologies and improving patient outcomes has fostered a conducive environment for the growth of the mRNA Therapeutics Market.

The Asia-Pacific region is emerging as a potential growth hub, with increasing investments in biotechnology and collaborations between local and international players. Countries like China, Japan, and South Korea are investing in the development of mRNA-based drugs, indicating future market expansion.

Key Players in the Market

The mRNA Therapeutics Market features key players such as Moderna, BioNTech, Pfizer, CureVac, and Arcturus Therapeutics, among others. These companies have been instrumental in advancing mRNA technology, from the development of vaccines to exploring new therapeutic applications. Strategic collaborations, mergers, and acquisitions are some of the strategies being employed to strengthen their positions in the market.

Conclusion

The mRNA Therapeutics Market is set for steady growth, driven by the ongoing research and development in the field, coupled with advancements in delivery systems and a supportive regulatory framework. As pharmaceutical companies continue to explore the potential of mRNA technology across a range of therapeutic areas, the market is expected to expand, offering new possibilities for treating various diseases.

[decentralvaccine]

Northwestern University Sues Moderna Over Patented Covid 19 Vaccine Technology

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid nanoparticles to develop its SpikeVax COVID-19 vaccine.

NU had a critical role in the development of the lipid nanoparticles, according to the complaint. The University also argued Moderna’s explicit use of the particles in its mRNA vaccine was a violation of the patent. The University is seeking “reasonable royalties” but did not specify how much money it expects from Moderna.

Moderna’s SpikeVax was first introduced to the market in December 2020. Last year, the company earned $6.7 billion in revenue from the vaccine.

https://dailynorthwestern.com/2024/10/22/campus/northwestern-files-lawsuit-against-moderna-seeks-royalties-for-covid-mrna-vaccine-technology/

[colinwilson11]

The Non-Viral Drug Delivery Systems Market To Grow Owing To Increasing Advantages Over Viral Delivery Methods

Non-viral drug delivery systems have gained immense popularity in recent years owing to their advantages over viral delivery methods including low immunogenicity, larger transgene capacity and ease of production. Non-viral techniques involve encapsulating drugs into nanoparticles, liposomes or conjugating them to targeting moieties and are generally considered safer than viral vectors.

The Non-Viral Drug Delivery Systems Market is estimated to be valued at US$ 8.1 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the non-viral drug delivery systems market are Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, eTheRNA Immunotherapies. The companies are investing heavily in R&D to develop novel non-viral vectors with higher efficiency and safety. The growing demand for targeted drug delivery systems is a major factor driving the non-viral drug delivery systems market. Non-invasive therapeutic delivery through oral, transdermal and inhalation routes has gained prominence. Technological advancements like lipid nanoparticles, polymeric nanoparticles and conjugation with cell-penetrating peptides have increased the delivery of macromolecules.

Market Trends

One of the major trends in the non-viral drug delivery systems market is the rising focus on gene therapy. Non-viral gene delivery methods offer less immunogenic and inflammatory responses making them safer for repeated administration. mRNA-based therapies and applications in cancer immunotherapy are emerging as lucrative opportunities. Another key trend is the development of stimuli-responsive delivery systems that are designed to release drug payloads in response to specific biochemical cues like pH, redox potential or enzymatic activity at the site of action.

Market Opportunities

Targeted delivery to tumors using actively/passively targeted nanoparticles presents a huge opportunity. The application of nanotechnology has allowed efficient delivery of anti-cancer drugs, imaging agents and nucleic acids selectively to tumor tissues. Oligonucleotide therapeutics also offer lucrative opportunities given the advances in mRNA vaccines. Non-invasive delivery through pulmonary route for treatment of lung cancers and respiratory diseases is an emerging area of focus.

Impact Of COVID-19 On Non-Viral Drug Delivery Systems Market Growth

The COVID-19 pandemic has significantly impacted the non-viral drug delivery systems market. During the initial phases of the pandemic, most non-essential research was put on hold or delayed, impacting the development of new drug delivery technologies. Companies focused their efforts on developing COVID-19 vaccines and therapeutics to address the urgent medical need. This diverted resources away from other drug delivery applications.

However, as the pandemic progressed, companies recognized the long-term market potential for non-viral delivery platforms to address future pandemics and other diseases. Nanoparticle-based delivery systems can effectively transport mRNA, DNA and protein therapeutics into cells, making them well-suited for developing new classes of antiviral drugs and vaccines. Several companies utilized their non-viral platforms to design COVID-19 vaccines and therapies during clinical trials.

Going forward, governments and healthcare agencies are expected to prioritize research into development capabilities for rapid responses to health emergencies. Non-viral delivery technologies can play a major role here through their ability to package different types of biologics and enable faster discovery processes compared to viral vectors. Companies are also advancing formulations tuned for stability at varying temperatures and extended shelf-life to address logistical challenges in vaccine distribution globally.

North America Dominates Non-Viral Drug Delivery Systems Market

The North America region currently dominates the Non-Viral Drug Delivery Systems Market in terms of value. This is due to presence of established pharmaceutical and biotechnology companies engaged in development and commercialization of delivery platforms for various biologics. Large companies have made significant investments setting up research centers focused on non-viral technologies.

Government funding for innovation is also strong through the National Institute of Health and Department of Defense programs. Academic research is rapidly advancing new formulations and delivery routes. The U.S. and Canada also have a well-developed regulatory system to approve new drug-device combination products incorporating non-viral carriers. High healthcare spends per capita contribute to faster market uptake of advanced therapeutics enabled by these platforms.

Asia Pacific Emerging As Fastest Growing Region

Going forward, the Asia Pacific region is expected to offer the fastest market growth opportunities for non-viral drug delivery systems. This is attributable to rising chronic disease prevalence in highly populated countries like China and India. Governments are investing significantly to build local R&D capabilities through initiatives such as the Made in China 2025 policy.

Countries like South Korea and Japan also have large biotechnology industries focusing on formulations. At the same time, reduced manufacturing and labor costs are attracting global pharmaceutical companies to outsource production to Asia Pacific contract development and manufacturing organizations. This will help expand regional production capacities for various non-viral technologies.

Get more insights on this topic:  https://www.ukwebwire.com/non-viral-drug-delivery-systems-market-are-estimated-to-witness-high-growth-owing-to-advancements-in-nanotechnology/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

What Are The Key Data Covered In This Non-Viral Drug Delivery Systems Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Non-Viral Drug Delivery Systems Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Non-Viral Drug Delivery Systems Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Non-Viral Drug Delivery Systems Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Non-Viral Drug Delivery Systems Market vendors

FAQ’s

Q.1 What are the main factors influencing the Non-Viral Drug Delivery Systems Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Non-Viral Drug Delivery Systems Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Non-Viral Drug Delivery Systems Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[thealphareporter]

Lipid Nanoparticles (LNPs) CDMO Market Analysis: Key Developments and Growth Projections

http://dlvr.it/TCtVtK

[newsheadlinesnow]

Lipid Nanoparticles (LNPs) CDMO Market Analysis: Key Developments and Growth Projections

http://dlvr.it/TCtTrd

[thesunshinereporter]

Lipid Nanoparticles (LNPs) CDMO Market Analysis: Key Developments and Growth Projections

http://dlvr.it/TCtP0f

[healthcaremarketanalysis]

Lipid Nanoparticles Market to Reach USD 350.5M by 2029

The Global Lipid Nanoparticles Market is expected to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, with a CAGR of 5.2%, while the LNP services market is projected to rise from USD 135.5 million in 2024 to USD 238.1 million by 2029 at a CAGR of 11.9%. Growth is driven by advancements in LNP-based pharmaceuticals, particularly in anti-cancer and mRNA therapies, though regulatory challenges and formulation issues pose potential constraints. Key opportunities include the demand for advanced drug delivery systems and scalable mRNA vaccines. The market's key players include Avanti Polar Lipids, Merck KGaA, and FUJIFILM Pharmaceuticals, with North America being the leading regional market. The sector is influenced by diverse product segments such as ionizable and PEGylated lipids, with applications spanning COVID-19 and cancer treatments.

Download PDF Brochure

Browse in-depth TOC on "Lipid Nanoparticles Market"

398 - Tables

53 - Figures

316 - Pages

Factors Influencing Market Trends

The expansion of the lipid nanoparticles market is driven by increasing research and development efforts to create lipid nanoparticle-based drugs. However, stringent regulatory requirements may impede growth.

Product Segment Insights

The market is segmented by product into ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials, with ionizable lipids leading due to their crucial role in mRNA vaccines like Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273.

LNP Type Breakdown

Segmented into solid lipid nanoparticles, nanostructured lipid carriers, and other types, the solid lipid nanoparticles segment holds the largest share, favored for vaccine production and as an alternative drug delivery carrier.

Molecule Type Distribution

The market is divided by molecule type into siRNA, mRNA, and other molecules. The mRNA segment dominates due to its effectiveness in vaccine production and the enhanced delivery capabilities of lipid nanoparticles.

Application Areas

Segmented into commercial and clinical applications, the commercial segment currently holds the largest market share due to its extensive use in vaccine production. The clinical applications segment, however, is expected to grow the fastest, driven by advancements in targeted drug delivery and personalized medicine.

End-User Analysis for Raw Materials

For raw materials, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and CDMOs, with pharmaceutical & biotechnology companies holding the largest share due to their high use of lipid nanoparticles in drug development.

Service Type Analysis

The lipid nanoparticles services market, categorized into formulation development services, manufacturing services, and other services, sees the largest share in manufacturing services. This is driven by the high demand for raw materials and ongoing requirements from pharmaceutical and biotechnology companies.

End-User Analysis for Services

The services market is segmented by end users into pharmaceutical & biotechnology companies and academic & research institutes, with pharmaceutical & biotechnology companies leading due to their need for specialized manufacturing services and expertise.

Regional Market Overview

The lipid nanoparticles market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the largest share in 2023, benefiting from advanced healthcare infrastructure and significant R&D investments. However, the Asia Pacific region is anticipated to be the fastest-growing market during the forecast period, driven by increased healthcare expenditure, government initiatives, and favorable regulatory conditions.

Request Sample Pages

Growth Drivers and Challenges

The growth of the lipid nanoparticles market is driven by their increasing use in anti-cancer and RNA-based therapies. However, stringent regulatory requirements related to lipid nanoparticles may pose challenges to market expansion.

Market Consolidation

The lipid nanoparticles market is largely consolidated, with major players such as Avanti Polar Lipids (Croda International plc), Merck KGaA, NOF CORPORATION, and Nippon Fine Chemical holding 70-75% of the global market share.

Company Profiles

Avanti Polar Lipids (US): Established in 1967, Avanti specializes in high-purity lipids for biochemical and pharmaceutical research. The company offers a broad portfolio of lipid nanoparticles and custom synthesis services, heavily investing in R&D and collaborating with academic institutions to advance lipid formulations.

Merck KGaA (Germany): This healthcare and life sciences company provides a range of lipid nanoparticles products for research and clinical applications. Merck KGaA has strengthened its RNA production capabilities and recently acquired Exelead for approximately USD 780 million to enhance its CDMO services.

NOF CORPORATION (Japan): NOF CORPORATION is a prominent chemical manufacturer known for its lipid nanoparticle formulations. In April 2024, NOF collaborated with Phosphorex to provide lipid nanoparticles using their COATSOME® SA Series, which offers efficient nucleic acid delivery with minimal toxicity. NOF continues to innovate with high-purity lipid derivatives and liposome formulations for various drug applications.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA : 1-888-600-6441

UK +44-800-368-9399

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

[universalnewspoint]

Lipid Nanoparticles (LNPs) CDMO Market Analysis: Key Developments and Growth Projections

http://dlvr.it/TCtGxz

[hopetribune]

Lipid Nanoparticles (LNPs) CDMO Market Analysis: Key Developments and Growth Projections

http://dlvr.it/TCtG2D

[creativeera]

The Ascending Potential of Liposome Drug Delivery Market is Driven by Nanotechnology

Liposome drug delivery refers to the technology enabling entrapment of therapeutic or cosmetic agents in liposomes which are artificially prepared vesicles made of lipid bilayers. Advances in nanotechnology have allowed for the development of liposomes as drug carriers that can fuse with cell membranes and deliver encapsulated drug payload at target sites within the body.

The liposome drug delivery market is estimated to be valued at USD 5,482.2 Mn in 2024 and is expected to reach USD 9,935.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Key Takeaways Key players operating in the liposome drug delivery market are Gilead Sciences, Inc., Luye Pharma Group, Ipsen Biopharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Acuitas Therapeutics, LIPOSOMA B.V., Takeda Pharmaceutical Company Limited, Taiwan Liposome Company, Ltd., Endo International, and Jazz Pharmaceuticals plc. These players are focusing on R&D activities to develop novel liposome formulations for various therapeutic applications. The growing demand for targeted drug delivery systems is expected to drive the demand for liposome drug delivery globally. Liposomes allow for selective delivery of encapsulated drugs to the intended site of action while preventing damage to healthy tissues. This reduces systemic side effects and enhances therapeutic efficacy. The Liposome Drug Delivery Market Growth is also witnessing significant expansion in emerging economies. Factors such as the growing geriatric population, rising investments in healthcare infrastructure, and increasing focus on nanomedicines are expected to boost market revenue in Asia Pacific, Latin America, and Middle East & Africa over the forecast period. Market Key Trends The use of advanced analytical techniques such as microfluidics and supercritical fluid technologies for production of liposomes is one of the key trends in the industry. These techniques allow for precision encapsulation of drugs, reproducible quality, and large scale manufacturing of liposomes. Liposome Drug Delivery Market Size and Trends promises to enhance drug delivery capabilities and facilitate commercialization.

Porter’s Analysis Threat of new entrants: High capital requirements and stringent regulations create barriers for new entrants in the liposome drug delivery market. Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative drug delivery technologies. Bargaining power of suppliers: Suppliers have moderate to high bargaining power due to their differentiated technologies and expertise required for liposome production. Threat of new substitutes: Technological improvements in alternative drug delivery systems like nanoparticle drug delivery pose a threat. Competitive rivalry: The liposome drug delivery market witnesses high competition due to the presence of major players. Geographical Regions North America holds the largest share in the liposome drug delivery market owing to the presence of major players and early adoption of advanced drug delivery technologies. The rising prevalence of cancer and increasing R&D investments have also boosted the regional market. The Asia Pacific region is expected to grow at the fastest pace during the forecast period. Factors such as growing healthcare expenditure, increasing awareness regarding advanced treatments, and expansion of key players into emerging markets will drive the liposome drug delivery market in the Asia Pacific region.

Get more insights on Liposome Drug Delivery Market

Discover the Report for More Insights, Tailored to Your Language

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)